Objective Clinical, radiologic, and molecular analysis of patients with genomic deletions upstream of the LMNB1 gene.
Results
Five patients from 3 independent families presented at ages ranging from 32 to 52 years with neurologic symptoms that included progressive hypophonia, upper and lower limb weakness and spasticity, and cerebellar dysfunction and MRIs characterized by widespread white matter alterations. Patients had unique nonrecurrent deletions upstream of the LMNB1, varying in size from 250 kb to 670 kb. Deletion junctions were embedded in repetitive elements. Expression analysis revealed increased LMNB1 expression in patient cells.
Conclusions
Our findings confirmed the association between LMNB1 upstream deletions and leukodystrophy previously reported in a single family, expanding the phenotypic and molecular description of this condition. Although clinical and radiologic features overlapped with those of autosomal dominant leukodystrophy because of LMNB1 duplications, patients with deletions upstream of LMNB1 had an earlier age at symptom onset, lacked early dysautonomia, and appeared to have lesser involvement of the cerebellum and sparing of the spinal cord diameter on MRI. aCGH analysis defined a smaller minimal critical region required for disease causation and revealed that deletions occur at repetitive DNA genomic elements. Search for LMNB1 structural variants (duplications and upstream deletions) should be an integral part of the investigation of patients with autosomal dominant adult-onset leukodystrophy. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Autosomal dominant leukodystrophy (ADLD, OMIM #169500) is a fatal, progressive neurologic disorder that presents in the 4th to 6th decade of life and primarily affects CNS myelin.
1,2
Patients present with progressive autonomic dysfunction, followed by disturbance of motor control as a result of cerebellar deficits and spasticity; death occurs 10-20 years after the onset of symptoms. [2] [3] [4] We have previously shown that ADLD is caused by a duplication of the lamin B1 gene (LMNB1, chr5q23.2), resulting in increased LMNB1 protein expression. 4, 5 Although only LMNB1 duplications have been definitively shown to cause ADLD, we recently identified a genomic deletion upstream of the LMNB1 gene in a single large pedigree (ADLD-1-TO) that resulted in an phenotype similar to ADLD caused by LMNB1 duplications. 6 As the mutation was identified in only a single family, it was difficult to unequivocally confirm the link between the LMNB1-associated deletions and the leukodystrophy phenotype.
In this report, we present the analysis of 3 novel families with genomic deletions of varying sizes upstream of the LMNB1. The identification of a larger cohort of patients allows us to confirm the association between LMNB1 upstream deletions and disease, define a broader phenotypic spectrum associated with the mutation, and acquire mechanistic insights into the cause of this genomic rearrangement.
Methods
Five patients, belonging to 3 independent families, were examined because of adult-onset neurologic dysfunction. Array comparative genomic hybridization (aCGH) using a custom array, bioinformatics, and expression analysis was performed as described earlier. 4, 6 Histopathologic analysis and brief clinical and MRI findings from patient DEL2-1 have been described previously. 7 Standard protocol approvals, registrations, and patient consents Clinical and radiologic evaluations took place under the guidelines of the respective institutional review boards, and all patients provided written informed consent.
Data availability statement
All data used in this study are included in this report or accompanying supplementary information.
Results
Clinical characteristics of the 5 patients are described in table 1 and e-supplementary clinical information (links.
lww.com/NXG/A135). The age at onset of neurologic symptoms ranged from 32 to 52 years. Presenting symptoms included dysarthria and hypophonia (4/5), poor dexterity (4/5), imbalance (3/5), weakness of the extremities, including asymmetrical weakness (3/5), tremor (2/5), and painful leg spasms (1). Of note, early involvement of the autonomic nervous system was notable in only 1 patient with orthostatic intolerance and urinary urgency. In 2 patients, urinary urgency and incontinence were late features of the disorder, occurring only after development of severe lower limb spasticity. Two patients indicated significant propensity for worsening of symptoms in relation to elevated environmental heat and humidity.
Four patients underwent brain MRI (figure 1); all had a corticospinal tract involvement extending from the upper frontal lobes to the cerebral peduncles. Three patients (DEL1-1, DEL2-1, and DEL3-1) had extensive symmetrical white matter hyperintensities in all cerebral lobes with a less affected periventricular rim on T2-weighted spinecho images. Patient DEL3-2 was unique, as she did not exhibit extensive lobar involvement compared with other patients. Of interest, the central parts of the pathologic areas in this patient showed a low signal intensity (SI) on T2-weighted fluid-attenuated inversion recovery images indicating high fluid content. The upper cervical spinal cord was seen in the sagittal brain images. The anteroposterior diameters at C II were below the normal range in all patients. MRI of the cervical and upper thoracic spine, obtained in DEL3-1 and DEL2-1, did not reveal atrophy at the lower levels, nor obvious SI alterations.
Patients were negative for mutations in known diseasecausing genes including LMNB1 duplications (e-supplementary clinical information, links.lww.com/NXG/A135). Subsequent analysis using a custom aCGH assay allowed us to identify and map deletions upstream of the LMNB1 gene (figure 2). Deletions were unique to each family and ranged from ;670 kb to ;250 kb extending to within 88 kb-4.8 kb upstream of the LMNB1 start codon, respectively (table e-1). Analysis of the deletion boundaries (including those from the previously published ADLD-1-TO deletion) revealed that 3 of the 4 boundaries were in Alu repeats. The telomeric end of the DEL3 deletion was situated in a long interspersed nucleotide element (LINE) repeat element. A careful examination of the centromeric end of this deletion revealed a 20-bp region that had a high degree of homology to LINE elements. Thus, all the deletion boundaries appear to be embedded in some type of Glossary aCGH = array comparative genomic hybridization; ADLD = autosomal dominant leukodystrophy; LINE = long interspersed nucleotide element; SI = signal intensity; TAD = topologically associated domain.
repetitive DNA element. Expression analysis revealed increased levels LMNB1 mRNA in cells from one of the patients (Del1-1), consistent with the report on the ADLD-TO family (table e-2). 6 
Discussion
Patients with deletions upstream of the LMNB1 gene had clinical and radiologic signs that exhibited both unique findings and partial overlap with ADLD due to LMNB1 duplications. Clinically, 4/5 patients presented at onset with speech symptoms including dysarthria and hypophonia. This has not been reported for ADLD with LMNB1 duplications, where the most common presenting feature was autonomic dysfunction. Onset of symptoms also appeared to be earlier in patients with deletions.
On MRI, cerebral white matter involvement was more extensive, especially in the temporal lobes in patients with deletions compared with those with duplications at the same ages. The periventricular rim was less severely affected than other pathologic lobar white matter in both patient groups. The corticospinal tracts were affected in both groups, but only in one of the deletion patients (DEL1-1) did this extend to the medulla oblongata. This was the only 1 of the 4 deletion patients having an abnormality in the cerebellar peduncles. This is in contrast to duplication patients who have early changes in the medulla oblongata and cerebellar peduncles. 2 Cerebral atrophy is not a prominent feature in patients with duplications, but marked atrophy was found in 1 of our patients (DEL 2-1) and in the previously reported Italian ADLD-1-TO family. 8 In patients with deletions, only the uppermost cervical spinal cord was atrophic, and in the 2 patients with a spinal MRI, no obvious SI changes were found in the rest of the cord. In LMNB1 duplication patients, the entire spinal cord is atrophic, and T2 signal in white matter is pathologic. This difference could explain the lack of early autonomic symptoms in patients with deletions, as it has been hypothesized that autonomic symptoms in ADLD with duplications are due to spinal cord involvement. 2 Analysis of the deletion events, which were clearly nonrecurrent, allowed us to define a minimal critical region of ;167 kb that is required for disease causation. Strikingly, this genomic region encompassed a boundary between 2 topologically associated domains (TADs) and strengthens our original hypothesis that a disruption of the TAD boundary causes LMNB1 overexpression and in turn the disease. 6 Sequencing the deletion junctions revealed the importance of repetitive elements (Alu, LINEs) in the genomic rearrangement. Their presence suggests that either a nonallelic homologous recombination mechanism or a microhomology-mediated break-induced repair type mechanism mediated by repeats is likely to cause the genomic deletions.
The identification of a larger cohort of patients confirms the pathogenic role of deletions upstream of LMNB1 in the leukodystrophy phenotype. Given that these mutations do not alter the coding sequence, our data also emphasize the importance of regulatory elements and the need for performing analyses for copy number variants that might be missed with the standard whole-exome sequencing, currently being used to identify mutations in patients with leukodystrophies. 
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